Last reviewed · How we verify

Maintenance on tacrolimus

Helio Tedesco Silva Junior · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Maintenance on tacrolimus is a Small molecule drug developed by Helio Tedesco Silva Junior. It is currently FDA-approved.

Tacrolimus is used as a maintenance immunosuppressive treatment for various conditions, including Type 1 Diabetes, Islet Transplantation, End Stage Renal Failure With Renal Transplant, Sickle Cell Disease, and Graft Versus Host Disease. It works by inhibiting the peptidyl-prolyl cis-trans isomerase FKBP1A through its action as a small molecule FK506-binding protein 1A inhibitor.

At a glance

Generic nameMaintenance on tacrolimus
SponsorHelio Tedesco Silva Junior
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Maintenance on tacrolimus

What is Maintenance on tacrolimus?

Maintenance on tacrolimus is a Small molecule drug developed by Helio Tedesco Silva Junior.

Who makes Maintenance on tacrolimus?

Maintenance on tacrolimus is developed and marketed by Helio Tedesco Silva Junior (see full Helio Tedesco Silva Junior pipeline at /company/helio-tedesco-silva-junior).

What development phase is Maintenance on tacrolimus in?

Maintenance on tacrolimus is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing